Clinical trial
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms…
NCT00198081 · Indiana University School of Medicine, Other · Terminated
Key facts
| NCT number | NCT00198081 |
|---|---|
| Title | Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs) |
| Official title | A Phase II Trial of Celecoxib in Patients With IPMN |
| Lead sponsor | Indiana University School of Medicine, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreas Neoplasms |
| Intervention type | Drug |
| Interventions | COX-2 Inhibitor 6-8 weeks prior to surgery, COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP |
| Enrollment | 8 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2012 |
| First posted | Sep 20, 2005 |
| Last update posted | Feb 29, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: